Sunovion Pharmaceuticals Inc.

Marlborough-based drug maker Sunovion Pharmaceuticals has partnered with pop singer Demi Lovato and others on a photo campaign to encourage responsible portrayals of mental health.

Marlborough drugmaker Sunovion Pharmaceuticals announced Friday it has purchased a company developing a Parkinson's disease treatment for approximately $635 million.

Marlborough's Sunovion has filed a new drug application with the U.S. Food and Drug Administration for ongoing treatment of chronic obstructive pulmonary disease that can make it difficult to breathe.

A six-week trial by Sunovion Pharmaceuticals Inc. found the drug candidate dasotraline was generally well-tolerated and demonstrated a statistically significant difference in children with ADHD.

Marlborough drug maker Sunovion Pharmaceuticals announced positive results Monday for dosing increases while using Latuda in treating people with schizophrenia.

Marlborough-based Sunovion Pharmaceuticals will seek regulatory approval for a new, quick-acting treatment of chronic obstructive pulmonary disease, after a final human trial reported positive results.

Marlborough-based Sunovion Pharmaceuticals announced a drug used to treat schizophrenia and bipolar depression was well-tolerated in patients and was associated with improved depressive symptoms in a secondary analysis.

Many of the top 100 employers in Central Massachusetts are from the state's biotech industry.

A long-term safety study of the effectiveness of Marlborough-based Sunovion Pharmaceuticals Inc.'s Brovana found the drug to be effective in reducing hospitalization in people with COPD.

Marlborough-based Sunovion Pharmaceuticals has received federal approval for its drug Aptiom as a monotherapy for the treatment of partial-onset epileptic seizures, the company announced.